Immix Biopharma Stock Performance
| IMMX Stock | USD 2.43 0.02 0.83% |
On a scale of 0 to 100, Immix Biopharma holds a performance score of 10. The company retains a Market Volatility (i.e., Beta) of 1.48, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immix Biopharma will likely underperform. Please check Immix Biopharma's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Immix Biopharma's current trending patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Immix Biopharma are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Immix Biopharma showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.83 | Five Day Return 10.45 | Year To Date Return 10.45 | Ten Year Return (33.79) | All Time Return (33.79) |
1 | Immix Biopharma Projected to Post Quarterly Earnings on Thursday - Defense World | 03/20/2025 |
2 | Acquisition by Marquet Magda of 16000 shares of Immix Biopharma at 2.64 subject to Rule 16b-3 | 03/21/2025 |
3 | Immix Biopharma Posts Quarterly Earnings Results, Beats Expectations By 0.09 EPS | 03/26/2025 |
4 | Immix Biopharmas NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO ... | 04/23/2025 |
5 | Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in ... | 05/21/2025 |
6 | Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsedrefractory AL Amyloidosi... | 05/22/2025 |
7 | Immix Biopharma Further Expands U.S. Clinical Sites for relapsedrefractory AL Amyloidosis ... | 05/23/2025 |
8 | Acquisition by Hsu Jason of 3200 shares of Immix Biopharma at 2.0748 subject to Rule 16b-3 | 05/28/2025 |
9 | Immix Sets Up ATM Agreement with Citizens JMP Securities IMMX Stock News | 06/03/2025 |
10 | Immix Biopharma Receives Reiterated Buy Rating from HC Wainwright Co. ... | 06/04/2025 |
11 | Immix Biopharma Upgraded to Buy What Does It Mean for the Stock | 06/06/2025 |
| Begin Period Cash Flow | 17.5 M |
Immix Biopharma Relative Risk vs. Return Landscape
If you would invest 165.00 in Immix Biopharma on March 14, 2025 and sell it today you would earn a total of 78.00 from holding Immix Biopharma or generate 47.27% return on investment over 90 days. Immix Biopharma is currently generating 0.8294% in daily expected returns and assumes 6.3857% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Immix, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immix Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immix Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immix Biopharma, and traders can use it to determine the average amount a Immix Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1299
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IMMX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.39 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.83 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Immix Biopharma is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immix Biopharma by adding it to a well-diversified portfolio.
Immix Biopharma Fundamentals Growth
Immix Stock prices reflect investors' perceptions of the future prospects and financial health of Immix Biopharma, and Immix Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immix Stock performance.
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.5 | ||||
| Current Valuation | 52.32 M | ||||
| Shares Outstanding | 27.88 M | ||||
| Price To Book | 6.80 X | ||||
| EBITDA | (21.54 M) | ||||
| Net Income | (21.7 M) | ||||
| Cash And Equivalents | 18.4 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.07 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 19.53 X | ||||
| Book Value Per Share | 0.34 X | ||||
| Cash Flow From Operations | (14.6 M) | ||||
| Earnings Per Share | (0.71) X | ||||
| Market Capitalization | 67.18 M | ||||
| Total Asset | 22.95 M | ||||
| Retained Earnings | (75.02 M) | ||||
| Working Capital | 11.51 M | ||||
About Immix Biopharma Performance
Evaluating Immix Biopharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immix Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immix Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.94) | (0.99) | |
| Return On Capital Employed | (1.59) | (1.51) | |
| Return On Assets | (0.94) | (0.99) | |
| Return On Equity | (1.63) | (1.55) |
Things to note about Immix Biopharma performance evaluation
Checking the ongoing alerts about Immix Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immix Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immix Biopharma is way too risky over 90 days horizon | |
| Immix Biopharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (21.7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immix Biopharma currently holds about 18.4 M in cash with (14.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Immix Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Immix Biopharma Upgraded to Buy What Does It Mean for the Stock |
- Analyzing Immix Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immix Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Immix Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immix Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immix Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immix Biopharma's stock. These opinions can provide insight into Immix Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.